Updates are available Correction dated 2022-07-26
Click to view Correction: https://doi.org/10.1007/s10911-022-09524-8
-
Authors
Souto, Eric P.
Dobrolecki, Lacey E.
Villanueva, Hugo
Sikora, Andrew G.
Lewis, Michael T. http://orcid.org/0000-0002-6330-4007
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA125123)
National Cancer Institute (CA224076, CA224867)
Cancer Prevention and Research Institute of Texas (RP170691)
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 19 May 2022
First Online: 13 June 2022
Change Date: 26 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10911-022-09524-8
Declarations
:
: M.T.L is a Founder of, and an uncompensated Limited Partner in StemMed Ltd., as well as an uncompensated a Manager in, StemMed Holdings L.L.C., its General Partner. He is a Co-founder of, and equity stake holder in, Tvardi Therapeutics Inc., a Houston based pharmaceutical development company L.D. is a compensated employee of StemMed Ltd. Selected BCM PDX models described herein are exclusively licensed to StemMed Ltd. resulting in royalties to M.T.L. and L.D. M.T.L is a member of the editorial board for the Journal of Mammary Gland Biology and Neoplasia.
